EQUI.TS GmbH is an innovative, equity research boutique based in Frankfurt (Germany). It is operated by its original founders and has established a reputation as a quality research provider over a period of more than 10 years. Although it generally does not focus on any particular branch of industry, its analyses often revolve around technology and growth stocks.
Regulatory Information
BUSINESS ACCOUNT
Access reports individually or via Subscription
Receive monthly invoices with payment via CSA or hard dollars
Analyst access
Free Trial Subscriptions
Team account with shared subscriptions
Advanced analytics to track research consumption and performance
Überraschend kräftig entwickelte sich Q3/20; BPS (+26 % auf € 144,5 Mio.) wuchs anhaltend zweistellig; LPS (+44,1 % auf € 478,7 Mio.) beendete (mit Wiedereröffnung der akademischen Labore) die Schwächephase des H1/20 in allen Regionen. Der Ordereingang erreichte € 711,7 Mio. (+54,5% ggü. Vj; in CC: +60% - davon ca. 30%-Punkte COVID-19-bedingt). Der Q3/20-Konzernumsatz stieg um +39,5 % ggü. Vj. (EMEA: +37,4%; Amerika: +38,7 %; Asia/Pacific: +27,3 %) auf € 623,2 Mio. So gesehen könnte die herrschende Konzern-Mittelfristperspektive angehoben werden, sofern die anlaufende 2. Corona-Welle nicht ...
Q3/20 developed surprisingly strongly; BPS (+26 % to € 144.5 m) continued to grow at double-digit rates; LPS (+44.1 % to € 478.7 m) ended the weak phase of H1/20 (with the reopening of academic laboratories) in all regions. Order intake reached € 711.7 m (+54.5 % vs. previous year; in CC: +60 % - thereof approx. 30 % points COVID-19 related). Consolidated sales in Q3/20 rose by +39.5 % year-on-year (EMEA: +37.4 %; America: +38.7 %; Asia/Pacific: +27.3 %) to € 623.2 m. Seen in this light, the prevailing medium-term outlook for the Group could be raised, provided that the ongoing second wave...
Q4/20 "will be strong" – Guidance concretization on CMD? Q3/20-EBITDA (adj.) was above consensus, but revenue growth was lower. The Q3/20 was also "on track" and expansive in its core business, but continued to suffer from Covid-19-related influences on the cosmetics business as well as some shifts to Q4. Q4 will also benefit from this and has been characterized by the CEO on 10/13/20 as "very strong" – therefore the guidance was confirmed. Our estimates were right.
Der Q3-EBITDA (adj.) lag über dem Consensus, doch das Umsatzplus darunter. Auch das Q3/20 war „on track“ und im Kerngeschäft expansiv, litt aber weiterhin unter Covid-19-bedingten Einflüssen auf das Kosmetikgeschäft sowie einigen Verschiebungen ins Q4. Dieses wird auch hiervon profitieren und vom CEO am 13.10.20 als „sehr stark“ charakterisiert – folglich wurde die Guidance bestätigt. Unsere Schätzungen passten. Der Q3/20-Konzernumsatz stieg auf € 349,2 Mio. (nom. -2,6 %; org. +0,4 %; adj. +2,1 %); das adj. EBITDA wuchs organisch um 1,8 % (adj. +8,6 %) auf € 75,0 Mio. (adj. EBITDA-Marge: +4...
CoVID-19 slowed down the very buoyant order intake (prelim. figures), albeit in Q3/20 (+ 13 % yoy). The book-to-bill ratio: 133 % (H1/20: 160 %). The M9/20 order intake totalled approx. € 3.04 billion + 50.7 % yoy (H1/20: + 76 %yoy). Business-sensitive customer groups were already holding back. 9M/20 sales (prelim.) rose to € 2.29 billion (CC: +23.6% year-on-year); 9M/20 EBIT reached € 228 million (previous year: € -2.9 million).
Überraschend kräftig entwickelte sich Q3/20; BPS (+26 % auf € 144,5 Mio.) wuchs anhaltend zweistellig; LPS (+44,1 % auf € 478,7 Mio.) beendete (mit Wiedereröffnung der akademischen Labore) die Schwächephase des H1/20 in allen Regionen. Der Ordereingang erreichte € 711,7 Mio. (+54,5% ggü. Vj; in CC: +60% - davon ca. 30%-Punkte COVID-19-bedingt). Der Q3/20-Konzernumsatz stieg um +39,5 % ggü. Vj. (EMEA: +37,4%; Amerika: +38,7 %; Asia/Pacific: +27,3 %) auf € 623,2 Mio. So gesehen könnte die herrschende Konzern-Mittelfristperspektive angehoben werden, sofern die anlaufende 2. Corona-Welle nicht ...
Q3/20 developed surprisingly strongly; BPS (+26 % to € 144.5 m) continued to grow at double-digit rates; LPS (+44.1 % to € 478.7 m) ended the weak phase of H1/20 (with the reopening of academic laboratories) in all regions. Order intake reached € 711.7 m (+54.5 % vs. previous year; in CC: +60 % - thereof approx. 30 % points COVID-19 related). Consolidated sales in Q3/20 rose by +39.5 % year-on-year (EMEA: +37.4 %; America: +38.7 %; Asia/Pacific: +27.3 %) to € 623.2 m. Seen in this light, the prevailing medium-term outlook for the Group could be raised, provided that the ongoing second wave...
Q4/20 "will be strong" – Guidance concretization on CMD? Q3/20-EBITDA (adj.) was above consensus, but revenue growth was lower. The Q3/20 was also "on track" and expansive in its core business, but continued to suffer from Covid-19-related influences on the cosmetics business as well as some shifts to Q4. Q4 will also benefit from this and has been characterized by the CEO on 10/13/20 as "very strong" – therefore the guidance was confirmed. Our estimates were right.
Der Q3-EBITDA (adj.) lag über dem Consensus, doch das Umsatzplus darunter. Auch das Q3/20 war „on track“ und im Kerngeschäft expansiv, litt aber weiterhin unter Covid-19-bedingten Einflüssen auf das Kosmetikgeschäft sowie einigen Verschiebungen ins Q4. Dieses wird auch hiervon profitieren und vom CEO am 13.10.20 als „sehr stark“ charakterisiert – folglich wurde die Guidance bestätigt. Unsere Schätzungen passten. Der Q3/20-Konzernumsatz stieg auf € 349,2 Mio. (nom. -2,6 %; org. +0,4 %; adj. +2,1 %); das adj. EBITDA wuchs organisch um 1,8 % (adj. +8,6 %) auf € 75,0 Mio. (adj. EBITDA-Marge: +4...
CoVID-19 slowed down the very buoyant order intake (prelim. figures), albeit in Q3/20 (+ 13 % yoy). The book-to-bill ratio: 133 % (H1/20: 160 %). The M9/20 order intake totalled approx. € 3.04 billion + 50.7 % yoy (H1/20: + 76 %yoy). Business-sensitive customer groups were already holding back. 9M/20 sales (prelim.) rose to € 2.29 billion (CC: +23.6% year-on-year); 9M/20 EBIT reached € 228 million (previous year: € -2.9 million).
